Allogene Therapeutics Inc (NASDAQ: ALLO) has seen a decline in its stock price by -1.08 in relation to its previous close of 2.76. However, the company has experienced a -3.53% decline in its stock price over the last five trading sessions. prnewswire.com reported 2024-09-16 that FDA evaluated RMAT application based on positive clinical data from ongoing Phase 1 study of P-BCMA-ALLO1; new clinical data from the study will be presented at the 21st International Myeloma Society Annual Meeting this month RMAT designation recognizes potential of P-BCMA-ALLO1 to address significant unmet needs of multiple myeloma patients and enables increased dialogue with FDA throughout the development process SAN DIEGO, Sept. 16, 2024 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to P-BCMA-ALLO1, an investigational stem cell memory T cell (TSCM)-based allogeneic CAR-T cell therapy in Phase 1/1b clinical development for the treatment of patients with relapsed/refractory multiple myeloma.
Is It Worth Investing in Allogene Therapeutics Inc (NASDAQ: ALLO) Right Now?
Additionally, the 36-month beta value for ALLO is 0.82. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ALLO is 136.57M and currently, short sellers hold a 28.51% ratio of that float. The average trading volume of ALLO on September 17, 2024 was 2.43M shares.
ALLO’s Market Performance
The stock of Allogene Therapeutics Inc (ALLO) has seen a -3.53% decrease in the past week, with a 19.22% rise in the past month, and a 18.70% gain in the past quarter. The volatility ratio for the week is 11.54%, and the volatility levels for the past 30 days are at 8.75% for ALLO. The simple moving average for the last 20 days is 2.67% for ALLO stock, with a simple moving average of -15.07% for the last 200 days.
Analysts’ Opinion of ALLO
Many brokerage firms have already submitted their reports for ALLO stocks, with Oppenheimer repeating the rating for ALLO by listing it as a “Outperform.” The predicted price for ALLO in the upcoming period, according to Oppenheimer is $11 based on the research report published on August 08, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ALLO reach a price target of $11. The rating they have provided for ALLO stocks is “Overweight” according to the report published on May 31st, 2024.
ALLO Trading at 1.82% from the 50-Day Moving Average
After a stumble in the market that brought ALLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.73% of loss for the given period.
Volatility was left at 8.75%, however, over the last 30 days, the volatility rate increased by 11.54%, as shares surge +4.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.22% upper at present.
During the last 5 trading sessions, ALLO fell by -2.47%, which changed the moving average for the period of 200-days by +21.06% in comparison to the 20-day moving average, which settled at $2.66. In addition, Allogene Therapeutics Inc saw -14.95% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALLO starting from Douglas Earl Martin, who proposed sale 28,310 shares at the price of $2.79 back on Aug 21 ’24. After this action, Douglas Earl Martin now owns shares of Allogene Therapeutics Inc, valued at $78,844 using the latest closing price.
MESSEMER DEBORAH M., the Director of Allogene Therapeutics Inc, sale 18,641 shares at $2.28 during a trade that took place back on Jun 18 ’24, which means that MESSEMER DEBORAH M. is holding 166,765 shares at $42,488 based on the most recent closing price.
Stock Fundamentals for ALLO
Current profitability levels for the company are sitting at:
- -3148.66 for the present operating margin
- -759.84 for the gross margin
The net margin for Allogene Therapeutics Inc stands at -3237.8. The total capital return value is set at -0.44. Equity return is now at value -48.94, with -39.28 for asset returns.
Based on Allogene Therapeutics Inc (ALLO), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -2.43. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -739.85.
Currently, EBITDA for the company is -287.05 million with net debt to EBITDA at 0.3. When we switch over and look at the enterprise to sales, we see a ratio of 5785.53. The receivables turnover for the company is 0.04for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.25.
Conclusion
In conclusion, Allogene Therapeutics Inc (ALLO) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
